BOWN
Bowen Acquisition Corp9.19
-0.01-0.11%
Nov 25, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
27.52MP/E (TTM)
-Basic EPS (TTM)
-0.22Dividend Yield
0%Recent Filings
10-Q
Q3 FY2025 results
Bowen Acquisition Corp posted a Q3 net loss of $394K, up from $825K profit y/y, driven by $113K formation costs and $367K loss from FPA liability fair-value change, despite $86K trust interest. Nine-month net loss hit $1.7M versus $2.4M profit y/y, with operating loss steady at $324K but FPA issuance loss of $1.9M and $336K financing expense offsetting $271K trust income; net loss exceeds operating by >20% due to FPA and financing items. Trust holds $8.2M at $11.29/share after heavy redemptions, cash at $18K, related-party promissory note $500K. Business combination with Qianzhi awaits regulatory approvals. SPAC deadline looms.
8-K
SPAC deadline extended
Bowen Acquisition Corp shareholders approved an amendment on December 12, 2025, extending the business combination deadline up to three one-month increments from December 14, 2025, to June 14, 2026. The proposal passed overwhelmingly with 2,612,224 for and 4,477 against out of 2,616,701 shares present. Extension buys time to close the pending deal with Shenzhen Qianzhi BioTechnology. Risks remain if conditions aren't met.
8-K
Nasdaq delisting imminent
Bowen Acquisition Corp faces Nasdaq delisting after missing its October 15, 2025 deadline to complete a business combination, as ruled in a Panel decision on October 30. Trading halts November 3 unless the Listing Council reverses it on appeal. No assurance of continued listing. SPACs tread water, but time ran out.
10-Q
Q2 FY2025 results
Bowen Acquisition Corp swung to a $750,303 net income for Q2 ended June 30, 2025, up from $816,754 a year earlier, yet the six-month loss hit $1,289,691 after heavy redemptions slashed the trust from $75.8M to $8.3M. Operating losses narrowed to $76,828 from $125,096 year-over-year, cushioned by $88,405 in trust interest, while a $755,837 fair-value gain on the FPA liability offset minor interest expenses. Cash dwindles to $17,556 amid a $1.9M working capital deficit, with $500,000 in related-party debt and $806,502 FPA liability hanging; the pending merger with Shenzhen Qianzhi BioTechnology awaits regulatory nods. Redemptions fueled the trust drain. Nasdaq delisting looms over low share count.
8-K
Nasdaq delisting threat hits SPAC
Bowen Acquisition Corp faces Nasdaq delisting after failing key listing rules, including a market value of listed securities below $50 million, fewer than 1.1 million publicly held shares, and under 400 total shareholders. Trading halted on July 15, 2025; the SPAC plans to appeal by July 22 to delay suspension set for July 24. It eyes compliance via its pending merger with Shenzhen Qianzhi BioTechnology, yet success remains uncertain. Delisting risks liquidity sharply.
BAYA
Bayview Acquisition Corp
11.63-0.01
BCAR
D. Boral ARC Acquisition I Corp
10.01-0.01
IBAC
IB Acquisition Corp.
10.45+0.00
QETA
Quetta Acquisition Corporation
11.20-0.05
RIBB
Ribbon Acquisition Corp
10.35+0.01
SOUL
Soulpower Acquisition Corporati
10.13+0.00
TACO
Berto Acquisition Corp.
10.13+0.00
UYSC
UY Scuti Acquisition Corp.
10.22+0.00
WLAC
Willow Lane Acquisition Corp.
11.86+0.45
YHNA
YHN Acquisition I Limited
10.65+0.00